PortalPublikationenResidual pathological stage at radical cystectomy significan...

Residual pathological stage at radical cystectomy significantly impacts outcomes for initial T2N0 bladder cancer.

Standard

Residual pathological stage at radical cystectomy significantly impacts outcomes for initial T2N0 bladder cancer. / Isbarn, Hendrik; Karakiewicz, Pierre I; Shariat, Shahrokh F; Capitanio, Umberto; Palapattu, Ganesh S; Sagalowsky, Arthur I; Lotan, Yair; Schoenberg, Mark P; Amiel, Gilad E; Lerner, Seth P; Guru, Sonpavde.

in: J UROLOGY, Jahrgang 182, Nr. 2, 2, 2009, S. 459-465.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Isbarn, H, Karakiewicz, PI, Shariat, SF, Capitanio, U, Palapattu, GS, Sagalowsky, AI, Lotan, Y, Schoenberg, MP, Amiel, GE, Lerner, SP & Guru, S 2009, 'Residual pathological stage at radical cystectomy significantly impacts outcomes for initial T2N0 bladder cancer.', J UROLOGY, Jg. 182, Nr. 2, 2, S. 459-465. <http://www.ncbi.nlm.nih.gov/pubmed/19524971?dopt=Citation>

APA

Isbarn, H., Karakiewicz, P. I., Shariat, S. F., Capitanio, U., Palapattu, G. S., Sagalowsky, A. I., Lotan, Y., Schoenberg, M. P., Amiel, G. E., Lerner, S. P., & Guru, S. (2009). Residual pathological stage at radical cystectomy significantly impacts outcomes for initial T2N0 bladder cancer. J UROLOGY, 182(2), 459-465. [2]. http://www.ncbi.nlm.nih.gov/pubmed/19524971?dopt=Citation

Vancouver

Isbarn H, Karakiewicz PI, Shariat SF, Capitanio U, Palapattu GS, Sagalowsky AI et al. Residual pathological stage at radical cystectomy significantly impacts outcomes for initial T2N0 bladder cancer. J UROLOGY. 2009;182(2):459-465. 2.

Bibtex

@article{c3f740639850439d9091a74173ae33b5,
title = "Residual pathological stage at radical cystectomy significantly impacts outcomes for initial T2N0 bladder cancer.",
abstract = "PURPOSE: We hypothesized that in patients with T2N0 stage disease at transurethral bladder tumor resection a lower residual cancer stage (P1N0 or less) at radical cystectomy may correlate with improved outcomes relative to those with residual P2N0 disease. MATERIALS AND METHODS: We analyzed 208 patients with T2N0 stage disease at transurethral bladder tumor resection whose tumors were organ confined at radical cystectomy (P2 or lower, pN0). None received perioperative chemotherapy. Kaplan-Meier as well as univariable and multivariable Cox regression models addressed the effect of residual pT stage at radical cystectomy on recurrence and cancer specific mortality rates. Covariates consisted of age, gender, grade, lymphovascular invasion, carcinoma in situ, number of lymph nodes removed and year of surgery. RESULTS: Residual pT stage at radical cystectomy was P0 in 24 (11.5%) patients, Pa in 9 (4.3%), PCIS in 22 (10.6%), P1 in 35 (16.8%) and P2 in 118 (56.7%). Median followup of censored patients was 55.7 months for recurrence and 52.1 months for cancer specific mortality analyses. The 5-year recurrence-free survival rates of patients with P0/Pa/PCIS, P1 and P2 stage disease were 100%, 85% and 75%, respectively. The 5-year cancer specific survival rates for the same cohorts were 100%, 93% and 81%, respectively. On multivariable analysis the effect of residual stage P1 or lower at radical cystectomy achieved independent predictor status for recurrence (adjusted HR 0.20, p = 0.002) and cancer specific mortality (adjusted HR 0.24, p = 0.02). CONCLUSIONS: Down staging from initial T2N0 bladder cancer at transurethral bladder tumor resection to lower stage at radical cystectomy significantly reduces recurrence and cancer specific mortality. Further validation of this finding is warranted.",
author = "Hendrik Isbarn and Karakiewicz, {Pierre I} and Shariat, {Shahrokh F} and Umberto Capitanio and Palapattu, {Ganesh S} and Sagalowsky, {Arthur I} and Yair Lotan and Schoenberg, {Mark P} and Amiel, {Gilad E} and Lerner, {Seth P} and Sonpavde Guru",
year = "2009",
language = "Deutsch",
volume = "182",
pages = "459--465",
journal = "J UROLOGY",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "2",

}

RIS

TY - JOUR

T1 - Residual pathological stage at radical cystectomy significantly impacts outcomes for initial T2N0 bladder cancer.

AU - Isbarn, Hendrik

AU - Karakiewicz, Pierre I

AU - Shariat, Shahrokh F

AU - Capitanio, Umberto

AU - Palapattu, Ganesh S

AU - Sagalowsky, Arthur I

AU - Lotan, Yair

AU - Schoenberg, Mark P

AU - Amiel, Gilad E

AU - Lerner, Seth P

AU - Guru, Sonpavde

PY - 2009

Y1 - 2009

N2 - PURPOSE: We hypothesized that in patients with T2N0 stage disease at transurethral bladder tumor resection a lower residual cancer stage (P1N0 or less) at radical cystectomy may correlate with improved outcomes relative to those with residual P2N0 disease. MATERIALS AND METHODS: We analyzed 208 patients with T2N0 stage disease at transurethral bladder tumor resection whose tumors were organ confined at radical cystectomy (P2 or lower, pN0). None received perioperative chemotherapy. Kaplan-Meier as well as univariable and multivariable Cox regression models addressed the effect of residual pT stage at radical cystectomy on recurrence and cancer specific mortality rates. Covariates consisted of age, gender, grade, lymphovascular invasion, carcinoma in situ, number of lymph nodes removed and year of surgery. RESULTS: Residual pT stage at radical cystectomy was P0 in 24 (11.5%) patients, Pa in 9 (4.3%), PCIS in 22 (10.6%), P1 in 35 (16.8%) and P2 in 118 (56.7%). Median followup of censored patients was 55.7 months for recurrence and 52.1 months for cancer specific mortality analyses. The 5-year recurrence-free survival rates of patients with P0/Pa/PCIS, P1 and P2 stage disease were 100%, 85% and 75%, respectively. The 5-year cancer specific survival rates for the same cohorts were 100%, 93% and 81%, respectively. On multivariable analysis the effect of residual stage P1 or lower at radical cystectomy achieved independent predictor status for recurrence (adjusted HR 0.20, p = 0.002) and cancer specific mortality (adjusted HR 0.24, p = 0.02). CONCLUSIONS: Down staging from initial T2N0 bladder cancer at transurethral bladder tumor resection to lower stage at radical cystectomy significantly reduces recurrence and cancer specific mortality. Further validation of this finding is warranted.

AB - PURPOSE: We hypothesized that in patients with T2N0 stage disease at transurethral bladder tumor resection a lower residual cancer stage (P1N0 or less) at radical cystectomy may correlate with improved outcomes relative to those with residual P2N0 disease. MATERIALS AND METHODS: We analyzed 208 patients with T2N0 stage disease at transurethral bladder tumor resection whose tumors were organ confined at radical cystectomy (P2 or lower, pN0). None received perioperative chemotherapy. Kaplan-Meier as well as univariable and multivariable Cox regression models addressed the effect of residual pT stage at radical cystectomy on recurrence and cancer specific mortality rates. Covariates consisted of age, gender, grade, lymphovascular invasion, carcinoma in situ, number of lymph nodes removed and year of surgery. RESULTS: Residual pT stage at radical cystectomy was P0 in 24 (11.5%) patients, Pa in 9 (4.3%), PCIS in 22 (10.6%), P1 in 35 (16.8%) and P2 in 118 (56.7%). Median followup of censored patients was 55.7 months for recurrence and 52.1 months for cancer specific mortality analyses. The 5-year recurrence-free survival rates of patients with P0/Pa/PCIS, P1 and P2 stage disease were 100%, 85% and 75%, respectively. The 5-year cancer specific survival rates for the same cohorts were 100%, 93% and 81%, respectively. On multivariable analysis the effect of residual stage P1 or lower at radical cystectomy achieved independent predictor status for recurrence (adjusted HR 0.20, p = 0.002) and cancer specific mortality (adjusted HR 0.24, p = 0.02). CONCLUSIONS: Down staging from initial T2N0 bladder cancer at transurethral bladder tumor resection to lower stage at radical cystectomy significantly reduces recurrence and cancer specific mortality. Further validation of this finding is warranted.

M3 - SCORING: Zeitschriftenaufsatz

VL - 182

SP - 459

EP - 465

JO - J UROLOGY

JF - J UROLOGY

SN - 0022-5347

IS - 2

M1 - 2

ER -